ClinicalTrials.gg
RecruitingNCT07783061Updated Oct 6, 2026

Reducing Cardiovascular Risks: The Role of Alcohol Use

An interventional study of Alcohol Abstinence and Control arm in Alcohol Drinking, Drinking Behavior and At-risk Drinking, sponsored by The University of Texas at Arlington. Recruiting at 1 site in United States. Open to participants aged 26 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by The University of Texas at Arlington · Not applicable, Interventional, and Prevention

Updated Oct 6, 2026Now RecruitingSite recruiting status changedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
26 Years to 49 Years
Sex
All
01

Study summary

The purpose of this study is to learn whether avoiding alcohol can improve heart and blood vessel health in adults who regularly drink alcohol and have high blood pressure. High blood pressure is a major risk factor for cardiovascular disease (CVD), including heart attack and stroke.

In this randomized, controlled trial, men and women aged 26 to 49 years who regularly consume alcohol and have high blood pressure will be assigned by chance to either stop drinking alcohol or continue their usual drinking habits for 8 weeks. Researchers will compare changes in blood pressure and other cardiovascular disease risk factors between the two groups.

The information gained from this study may help researchers and health care providers better understand the effects of alcohol consumption on cardiovascular health and whether alcohol abstinence can reduce heart disease risk, especially in adults with high blood pressure.

Read the detailed description

The overarching objective is to determine the effect of alcohol abstinence on cardiovascular disease risks in individuals who consume alcoholic beverages over the recommended limits. After baseline assessment, participants will be randomly assigned to receive one of the interventions: either continue their usual drinking habits or to abstain from alcohol drinking. Before and after the 8-week intervention, blood pressure and sub-clinical cardiovascular disease risk factors (including arterial stiffness, endothelial function, and sympathetic nerve activity) will be measured. A longitudinal assessment of objective sleep will be performed throughout the study participation. Participants will be asked to maintain their diet and physical activity throughout the study.

02

Conditions studied

  • Alcohol Drinking
  • Drinking Behavior
  • At-risk Drinking
  • Cardiovascular Risk Factor
  • High Blood Pressure
03

In context

Alcohol Drinking

701 studies on the registry are indexed under Alcohol Drinking; 133 are open to participants now.

This study's planned enrollment of 148 is above the median of 122 across 607 interventional studies indexed under Alcohol Drinking.

Browse Alcohol Drinking studies →

Lead sponsor

The University of Texas at Arlington is the lead sponsor of 39 studies on the registry; 12 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
26 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 26 to 49 years
  • At-risk drinkers who drink over the recommended limits, defined as those with PEth (≥20 ng/dL) or those with a U.S. Alcohol Use Disorders Identification Test (USAUDIT) score ≥8/7 for men/women
  • Elevated blood pressure or hypertension (systolic blood pressure: 120-160 mmHg and/or diastolic blood pressure 80-100 mmHg)

Exclusion criteria

Exclusion criteria

  • History of CVD or cardiovascular events (e.g., stroke, myocardial infarction)
  • The presence of myocardial ischemia or arrhythmias with abnormal and blood pressure during a clinically-supervised maximal graded exercise test
  • Hypertension (systolic >160 mmHg and diastolic >100 mmHg)
  • On more than one anti-hypertensive medication, or on other physician-prescribed medications (but not including oral )
  • Major psychiatric disorders, including autism, ADHD, bipolar disorder, major depression, schizophrenia, and substance use disorders
  • Alcohol use disorder, PEth ≥400 ng/mL, or USAUDIT score ≥ 25
  • Current or history of any tobacco use in the past 6 months (including, but not limited to, cigarettes, e-cigarettes, hookah, Nicorette, snus and chewing tobacco)
  • Current or history of illicit and recreational drug use (more than 3 times in the past month and more than 15 times in their lifetime)
  • Diabetes type 1 \& type 2 with fasting blood glucose ≥126 mg/dL
  • Presence of renal disease with a creatinine > 1.5 mg/dL
  • Presence of liver disease with liver enzymes > 3x the
  • Anemia with a \< 8 g/dL
  • Diagnosis of chronic inflammatory disease such as, but not limited to, cancer
  • Diagnosis of chronic diseases such as, but not limited to lupus, multiple sclerosis, rheumatoid arthritis
  • Diagnosis of , pulmonary fibrosis, pneumonia, lung cancer, and cystic fibrosis
  • Diagnosis of neurological diseases, including seizure disorders, Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, and peripheral neuropathies
  • \<18.5 or ≥40 kg/m2
  • Unstable body weight (>5% change during the past 6 months)
  • Obstructive sleep apnea
  • Night-shift work
  • Women who are pregnant (or intend to become pregnant while participating in study), breastfeeding, or
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
148 participants (estimated)

Study arms

  • Other
    Usual Drinking Habits (Control)

    Participants will continue their usual alcohol consumption patterns during the study period and will be instructed not to change their lifestyle including alcohol use, diet, and habitual physical activity.

    Other: Control arm

  • Experimental
    Alcohol Abstinence Intervention

    Participants will be instructed to abstain from alcohol for 8 weeks. Throughout the study period, participants will be asked to maintain their usual diet and level of physical activity and avoid making other lifestyle changes, except for abstaining from alcohol.

    Behavioral: Alcohol Abstinence

Interventions

  • BehavioralAlcohol Abstinence

    Participants will be instructed to abstain from alcohol for 8 weeks and maintain their usual lifestyle, including diet and physical activity. One week before the intervention, participants will be provided with an Oura Ring and instructed to wear it throughout the study. Every two weeks, participants will meet virtually with the research team (approximately 45 minutes) to receive educational materials and personalized feedback based on phosphatidylethanol (PEth), sleep, and heart rate variability data to support alcohol abstinence. During these meetings, participants will also complete assessments of alcohol use, physical activity, and dietary intake. At week 4, participants will complete a dried blood spot PEth test. Participants will also receive weekly reminders by text message or email to ensure Oura Ring data are uploaded successfully.

  • OtherControl arm

    Participants will be asked to maintain their usual lifestyle, including alcohol consumption, diet, and physical activity, and will not have access to their study data during the intervention. One week before the intervention, participants will be provided with an Oura Ring and instructed to wear it throughout the study. Every two weeks, participants will meet virtually with the research team (approximately 45 minutes) to complete questionnaires on alcohol use, physical activity, and diet. At week 4, participants will complete a dried blood spot phosphatidylethanol (PEth) test. Participants will also receive weekly reminders by text message or email to ensure Oura Ring data are uploaded successfully.

06

What researchers measure

Primary outcomes

  1. Change in in-laboratory central and peripheral blood pressure

    In-laboratory central blood pressure will be measured after a 10-min rest in supine position, while in-laboratory peripheral blood pressure will be measured after a 10-min rest in seated position.

    Time frame: Baseline and after the 8-week intervention

  2. Change in nighttime central and peripheral blood pressure

    Blood pressure during nighttime (or sleep) will be measured by using a portable blood pressure monitor.

    Time frame: Baseline and after the 8-week intervention

Secondary outcomes

  1. Change in arterial stiffness

    Carotid to femoral pulse wave velocity (cfPWV), the gold standard for noninvasive arterial stiffness assessment, will be measured.

    Time frame: Baseline and after the 8-week intervention

  2. Change in endothelial function as measured by brachial artery flow-mediated dilation (FMD)

    Brachial artery flow-mediated dilation (FMD), a noninvasive measure of endothelial function, will be assessed using ultrasound.

    Time frame: Baseline and after the 8-week intervention

  3. Change in muscle sympathetic nerve activity (MSNA)

    Muscle sympathetic nerve activity (MSNA) in the leg will be measured at rest using microneurography, a direct invasive assessment of sympathetic neural outflow.

    Time frame: Baseline and after the 8-week intervention

Other outcomes

  1. Objective sleep

    A longitudinal assessment of objective sleep will be performed with Oura rings.

    Time frame: During the study participation (10 weeks).

07

Study locations

1 of 1 sites recruiting
  • Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington
    Arlington, Texas 76010, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant data collected during this study will be submitted to the NIMH Data Archive (NDA). These data will be made available to qualified researchers for scientific research, educational purposes, and other research-related activities in accordance with NDA data access policies.

Access criteria: Submit a Data Access Request to NDA and get approval.

Data sharing details ↗ · nda.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Aug 2031, 58 months later.

Of 328 non-industry interventional studies with no phase under Alcohol Drinking, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 58 months is above that.

Counting every sponsor, half of 336 studies reached it within 24 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 24, 2026
StartEst.
Oct 2026
Primary completionEst.
Aug 2031
CompletionEst.
Sep 2031
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington is now Recruiting
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Recruiting
    Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07783061
Lead sponsor
The University of Texas at Arlington
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
Oct 2026 (estimated)
Primary completion
Aug 2031 (estimated)
Completion
Sep 2031 (estimated)
Last update
Oct 6, 2026

Study contacts

Chueh-Lung Hwang, PhD, PT
Contact
chuehlung.hwang@uta.edu
8172729722

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion